biostudies-literatureVeltri GAssociazione Italiana per la Ricerca sul CancroFondazione Cassa di Risparmio di Padova e RovigoFondazione Umberto VeronesiAssociazione Italiana Contro le Leucemie-Linfomi e MielomaAssociazione Italiana per la ricerca sul cancroFondazione Città della Speranza Istituto di Ricerca Pediatricaprogetti di rilevante interesse nazionale3724https://www.ebi.ac.uk/biostudies/studies/S-EPMC8345121biostudies-literatureUnknown13(15)Lymphoblastic lymphoma (LBL) is the second most common type of non-Hodgkin lymphoma in childhood, mainly of T cell origin (T-LBL). Although current treatment protocols allow a complete remission in 85% of cases, the second-line treatment overall survival for patients with progressive or relapsed disease is around 14%, making this the major issue to be confronted. Thus, we performed a Reverse Phase Protein Array study in a cohort of 22 T-LBL patients to find reliable disease risk marker(s) and new therapeutic targets to improve pediatric T-LBL patients' outcome. Interestingly, we pinpointed JAK2 Y1007-1008 as a potential prognosis marker as well as a therapeutic target in poor prognosis patients. Hence, the hyperactivation of the JAK1/2-STAT6 pathway characterizes these latter patients. MorCancersRuxolitinib as a Novel Therapeutic Option for Poor Prognosis T-LBL Pediatric Patients.PMC834512119/0817/07_1FCR2177120178S4EK9AIL-TV191862064Gallingani ISerafin VVeltri GMussolin LBresolin SLovisa FCarraro EVencato SSandei MBiffi AAccordi BPillon MSilvestri CCortese GBasso GfalseRuxolitinib as a Novel Therapeutic Option for Poor Prognosis T-LBL Pediatric Patients.Lymphoblastic lymphoma (LBL) is the second most common type of non-Hodgkin lymphoma in childhood, mainly of T cell origin (T-LBL). Although current treatment protocols allow a complete remission in 85% of cases, the second-line treatment overall survival for patients with progressive or relapsed disease is around 14%, making this the major issue to be confronted. Thus, we performed a Reverse Phase Protein Array study in a cohort of 22 T-LBL patients to find reliable disease risk marker(s) and new therapeutic targets to improve pediatric T-LBL patients' outcome. Interestingly, we pinpointed JAK2 Y1007-1008 as a potential prognosis marker as well as a therapeutic target in poor prognosis patients. Hence, the hyperactivation of the JAK1/2-STAT6 pathway characterizes these latter patients. Mor2021-01-01T00:00:00Z2021 Jul2026-04-08T07:48:02.646Z2022-02-11T05:45:52.51ZS-EPMC83451213435962810.3390/cancers13153724